

# Joint MHRA/MedDRA Information Day

## MedDRA in the Pharmacovigilance Regulatory Process

Event #14505

08 December 2014

Holiday Inn Kensington Forum



### Programme Committee

**Sabine Brosch**

Monitoring and Incident Management  
Pharmacovigilance Department, European  
Medicines Agency (EMA), EU

**Mick Foy**

Group Manager, Vigilance Intelligence and  
Research Group, Medicines and Healthcare  
Products Regulatory Agency (MHRA), UK

**Patrick Revelle**

MedDRA Maintenance and Support Services  
Organization (MSSO), Director, USA



**MedDRA**

Medical Dictionary  
for Regulatory Activities

### Overview

The Medical Dictionary for Regulatory Activities (MedDRA) terminology is designed to assist the sharing, assessment and evaluation of medical information in relation to the authorisation, the safety monitoring and continuous benefit risk assessment of medicines.

This Information Day will provide attendees with a highlight of the latest MedDRA initiatives and developments. This will include an outline of various efforts of the MedDRA MSSO to support interoperability of MedDRA with other terminologies specifically in the healthcare domain and the use of MedDRA in coding and analysing medication errors.

The use of social media and other emerging technologies in pharmacovigilance and the potential role of MedDRA in facilitating data capture and analysis will be one of the key topics of the meeting.

In addition, practical aspects on the use of MedDRA in the context of the new ICH E2B(R3) ICSR format will be outlined thus allowing participants to obtain a better understanding of the impact on their future coding processes. This will be complemented by an outline of MHRA of frequently observed coding mistakes as part of the current ICSR reporting practices. The Information Day will conclude with a session that is dedicated to the use of MedDRA for signal detection and data analysis both from a regulator's and industry perspective.

### Key Topics

- MedDRA in the context of the use of social media and other emerging technologies in pharmacovigilance
- MedDRA and interoperability efforts in the healthcare domain
- Review of MedDRA scope and potential impact on MedDRA users
- Use of MedDRA for coding of medication errors
- Frequently observed coding errors by MHRA as part of ICSRs reporting
- Use of MedDRA for signal detection and data analysis
- Practical MedDRA coding aspects in the context of the new ICH E2B(R3) ICSR

### Who Will Attend

This programme will benefit Qualified Persons Responsible for Pharmacovigilance (QPPVs) and individuals involved in:

- Pharmacovigilance
- Coding of ICSRs
- Signal detection and evaluation
- Clinical development
- Safety databases

### Details of the Information Day

**Location:**

Holiday Inn London – Kensington Forum  
97 Cromwell Road  
London SW7 4DN  
United Kingdom



**DIA** DEVELOP  
INNOVATE  
ADVANCE

Session Co-chairs for this Information Day:  
**Mick Foy**, MHRA and **Patrick Revelle**, MSSO

## 08:45 REGISTRATION

## 09:00 WELCOME NOTE

Mick Foy, MHRA

## 09:15 Session 1

### MEDDRA DEVELOPMENTS TO MEET NEW PHARMACOVIGILANCE NEEDS

This session will provide an update on recent activities to ensure the continuing development of MedDRA to meet evolving pharmacovigilance needs and will focus on the coding and analysis of medication errors, off label use, and product quality issues.

**Scope of MedDRA – Update on Blue Ribbon Panel Meeting**  
 Judy Harrison, MSSO, US

**Use of MedDRA for coding Medication Errors in ICSRs**  
 Victoria Newbould, EMA, EU

**How the MedDRA Hierarchy Can Help – retrieving Medication Errors, Off Label Use, and Product Quality Issues**  
 Judy Harrison, MSSO, US

## 10:45 COFFEE BREAK

## 11:00 SESSION 2

### CAPTURING NEW DATA RESOURCES IN PHARMACOVIGILANCE

This session will look at the possibilities of harnessing social media data to inform pharmacovigilance activities and address the activities taking place to ensure natural language from these data can be mapped to the MedDRA hierarchy.

**Building a dictionary to translate internet vernacular to MedDRA**  
 Nabarun Dasgupta, University of North Carolina, US

**How MedDRA could support data analytics in the context of the IMI WEB RADR project**  
 Patrick Revelle, MSSO, US

**Harnessing Social Media for Pharmacovigilance – view from the industry**  
 Tjark Reblin, VP Safety Evaluation and Risk Management – UK Development GlaxoSmithKline, UK

## 12:45 LUNCH BREAK

### ABOUT DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation headquartered in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China.

Unless otherwise disclosed, DIA Europe acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA Europe. Speakers and agenda are subject to change without notice. Recording during DIA Europe sessions is strictly prohibited without prior written consent from DIA Europe.

## 13:30 SESSION 3

### NEW ICH E2B(R3) ICSR AND MEDDRA CODING

This session will provide explanations on how to use MedDRA in the new ICH E2B (R3) format in the context of the electronic reporting of adverse reactions in the EU. The expected benefits and the impact on the pharmacovigilance business processes will be highlighted. This will be followed by a discussion MedDRA coding best practices from a regulatory perspective and will include the highlights of a survey of industry users on MedDRA coding practices.

**How to use MedDRA in the new ICH ICSR E2B(R3) format**  
 Gaby Danan, pharmacovigilance expert, FR

**MedDRA coding best practices from a regulatory perspective**  
 Tahira Jan, MHRA, UK

**Results of MedDRA Coding Practices Survey**  
 Barry Hammond, Terminologieze Ltd, UK

## 15:00 COFFEE BREAK

## 15:30 SESSION 4

### MedDRA FOR SIGNAL DETECTION AND DATA ANALYSIS

This session will provide important insight into the use of MedDRA for signal detection and data analysis including an overview of the key aspects described in the ICH-endorsed "MedDRA Data Retrieval and Presentation: Points to Consider" document. Various approaches to data analysis such as the use of the MedDRA hierarchy and secondary System Organ Class (SOC) analyses will be presented. Standardised MedDRA Queries and their application in case identification and signal detection will be discussed. The presentations will provide both a regulatory and industry perspective on this topic.

**Use of MedDRA in signal detection and evaluation**  
 Phil Tregunno, Signal Management Unit Manager, MHRA, UK

**Safety signals, data retrieval and analysis – Industry Perspective**  
 Christina Winter, Medical Director, GSK, Global Clinical Safety and Pharmacovigilance, UK

## 17:00 END OF INFORMATION DAY

### HOTEL INFORMATION

DIA has booked a limited number of rooms at the following hotel:

Holiday Inn London – Kensington Forum  
 97 Cromwell Road  
 SW7 4DN London  
 United Kingdom

Tel.: +44 207 341 8000  
 Website: <http://www.hikensingtonforumhotel.co.uk/>

at the rate of:  
 GBP 157.00 per room/night inclusive of breakfast and VAT.

In order to make your reservation, please contact the hotel directly at + 44 (0) 207 341 3355 and quote the booking reference PON.

Important: The room rate is available until 20 October 2014 or until the group block is sold-out, whichever comes first.

# REGISTRATION FORM

ID #14505 | 08 December 2014 | Holiday Inn Kensington Forum

**DIA** DEVELOP  
INNOVATE  
ADVANCE

FAX YOUR COMPLETED REGISTRATION FORM TO: +41 61 225 51 52 or email to: [diaeuropa@diaeuropa.org](mailto:diaeuropa@diaeuropa.org)

## FEES

Standard fee	€ 500.00	<input type="checkbox"/>
Reduced fee for Academia/Non-profit (Full-time)	€ 250.00	<input type="checkbox"/>
Reduced fee for Government	€ 250.00	<input type="checkbox"/>

The registration fee includes meeting material, sandwich lunch and refreshments.

**TOTAL AMOUNT DUE:** \_\_\_\_\_

Payment is due 30 days after registration and must be paid in full by commencement of the event.

## ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee's business card here.

☐ Prof ☐ Dr ☐ Ms ☐ Mr

Last Name

First Name

Company

Job Title

Address

Postal Code  City

Country

Telephone

Fax

Email\*

\*(Required for confirmation)

DIA reserves the right to include your name and affiliation on the attendee list.

## PAYMENT METHODS

**Credit cards:** Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.

☐ Please charge my ☐ VISA ☐ MC ☐ AMEX

Card N°

Exp. Date  /

Cardholder's Name

☐ **Bank transfers:** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Event ID #14504 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. **If you have not received your confirmation within five working days, please contact DIA Europe.**

By signing below, I confirm that I agree with DIA Europe's Terms and Conditions of booking. These are available from the office or on <http://www.diahome.org/EUTerms>

Date <input type="text"/>	Signature <input type="text"/>
---------------------------	--------------------------------

### Cancellation Policy

All cancellations must be made in writing and be received at the DIA Europe office five working days prior to the event start date. Cancellations are subject to an administrative fee:

- Industry € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) € 100.00

If you do not cancel five working days prior to the event start date and do not attend, you will be responsible for the full registration fee. DIA Europe reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA Europe is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

### Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA Europe office of any such substitutions as soon as possible.

### Photography Policy

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA Europe in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.

The DIA Europe Customer Services Team will be pleased to assist you with your registration from Monday to Friday between 08:00 and 17:00 CET.

Email [diaeuropa@diaeuropa.org](mailto:diaeuropa@diaeuropa.org) Tel. +41 61 225 51 51 Fax +41 61 225 51 52 Web [www.diaeuropa.org](http://www.diaeuropa.org) Mail DIA Europe, Kùchengasse 16, 4051 Basel, Switzerland © DIA 2014